Currency in SEK
Last close As at 06/02/2023
▲ −0.09 (−2.97%)
Scandion Oncology is focused on the development of add-on therapies to reverse chemotherapy resistance in oncology. Lead asset SCO-101 is in a Phase II trial for mCRC and a Phase Ib trial for pancreatic cancer.
Tumours often develop resistance to chemotherapeutic regimens. Widely available drugs, such as irinotecan and paclitaxel, are commonly associated with tumour resistance. The existence of add-on therapies to reverse resistance of this type will be an attractive prospect to many clinicians, in our view.
|52 week high/low||SEK17.6/SEK1.9|
Scandion Oncology is a biotechnology company focused on the development of add-on therapies to reverse chemotherapy resistance in oncology. The company’s lead asset SCO-101 is currently in a Phase II trial for metastatic colorectal cancer (mCRC) and a Phase Ib trial for pancreatic cancer. In H222 management undertook a rights issue, raising c SEK75m gross, mainly to fund the expansion of the SCO-101 clinical development programme to include patients harbouring RAS mutations. As such, part 3 of the CORIST trial in mCRC began enrolment in October 2022. While top-line readouts from the CORIST part 2 mCRC trial did not achieve the primary endpoint for efficacy, patients are continuing treatment and longer-term efficacy benefits may be realised. We estimate that the company is funded into FY24. We value Scandion Oncology at SEK241.1m or SEK5.9/share.
|Y/E Dec||Revenue (DKKm)||EBITDA (DKKm)||PBT (DKKm)||EPS (ore)||P/E (x)||P/CF (x)|